For further details see:
Cassava Sciences reports positive simufilam data with SavaDx in mid-stage Alzheimer’s studyFor further details see:
Cassava Sciences reports positive simufilam data with SavaDx in mid-stage Alzheimer’s studyMarket Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Cassava Sciences Inc. Company Name:
SAVA Stock Symbol:
Market:
An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going Phase 3 Trials. The DSMB Recommended Both Phase 3 Trials Continue as Planned, Without Modification. Final Clinical Safety Data for S...
2024-03-20 04:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-12 10:37:00 ET Cassava Sciences Inc (NASDAQ: SAVA) is in focus today after it again came under scrutiny over research involving its Alzheimer’s drug. FDA report questions Alzheimer’s drug trial results of $SAVA An FDA (Food & Drug Administration) report...